CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Analysts
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and nine have assigned...